Genetic data suggest inflammatory bowel disease should be divided into three categories instead of the current split between Crohn's disease and ulcerative colitis. UK researchers say their findings suggest Crohn's disease can be more specifically classified as either ileal Crohn's disease or colonic Crohn's disease, which could help clinicians make better individual treatment decisions.
Allergan is seeking FDA's approval to expand the use of Lap-Band surgery to youths as young as 14 to curb obesity, saying clinical trials to test the device's safety are under way. However, doctors and health experts said there is insufficient evidence of the device's long-term safety and effectiveness and noted that the surgery should only be a last option for morbidly obese people.
Hepatitis C patients who refused treatment to wait for more effective drugs may overload the system as they seek new medications such as boceprevir and telaprevir and cause shortages and ethical issues for providers, say researchers from the University of Chicago. The report, published in the journal Hepatology, suggested a needs-based plan giving the sickest HCV patients first access to the drugs with the rest prioritized based on disease progression, beginning with those who have cirrhosis.
It's important to know the difference between inflammatory bowel disease and irritable bowel, especially since symptoms can be similar, experts say. IBD or ulcerative colitis and Crohn's disease are autoimmune diseases that have pathologic abnormalities, while IBS does not and may have sporadic symptoms.
U.S. researchers are examining genetic mutations linked to Crohn's disease, ulcerative colitis and other irritable bowel conditions in hopes of developing personalized treatments based on stem cells. They hope to use induced pluripotent stem cells to repair the NOD2 genetic mutation that is related to Crohn's.